Debiopharm, Sigma-Tau Acute Heart Failure Candidate Delivers Strong Phase IIa
This article was originally published in The Pink Sheet Daily
First-in-class luso-inotropic agent improved systolic and diastolic functions in patients with decompensated heart failure.
You may also be interested in...
Swiss-based Debiopharm is seeking European marketing partners for its somatostatin analog Sanvar (vapreotide acetate), the company said July 24
The European Medicines Agency says its rolling review tool should speed up the evaluation of AstraZeneca’s COVID-19 vaccine.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.